IMV Inc.

  • Home
  • About Us
    • Overview
    • Management Team
    • Board of Directors
    • Scientific & Clinical Advisors
    • Partnerships
  • The DPX Platform
    • Overview
    • Scientific Publications & Posters
  • Clinical Pipeline
    • Overview
    • DPX-Survivac
    • DPX-RSV
    • DPX-COVID-19
    • Clinical Trials
  • News & Events
    • Press Releases
    • Events
    • Email Alerts
  • Investors
    • Overview
    • Press Releases
    • Events, Webcasts & Presentations
    • Financial Info
    • Stock Data
    • Filings
    • Governance
    • Contact Us
    • FAQ
  • Careers
    • Overview
    • Life at IMV
  • Contact

Press Releases

Investors

Investors

  • Overview
  • Press Releases
  • Events, Webcasts & Presentations
    • Overview
    • Presentations
    • Scientific Publications & Posters
    • Email Alerts
  • Financial Info
    • Financial Results
    • Tax Info
    • Proxy Info
    • Stock Option Plan
    • Deferred Share Unit Plan
  • Stock Data
    • NASDAQ: IMV
    • TSX: IMV
    • Analyst Coverage
  • Filings
    • SEC Filings
    • SEDAR
  • Governance
    • Board of Directors
    • Board Committees
    • Governance Documents
  • Contact Us
  • FAQ
Oct 30, 2019 7:05am EDT

IMV Appoints Joanne Schindler, M.D., D.V.M. as Chief Medical Officer

Oct 29, 2019 7:05am EDT

IMV Inc. to Announce Third Quarter 2019 Results and Host a Conference Call and Webcast on November 8, 2019

Oct 16, 2019 10:01am EDT

/ C O R R E C T I O N From Source – IMV Inc /

Oct 11, 2019 7:05am EDT

IMV Inc. to Present at Upcoming Investor Conference

Sep 30, 2019 3:00am EDT

Preliminary Results From IMV’s Phase 2 Basket Trial Evaluating DPX-Survivac as a Combination Therapy in Patients With Advanced and Metastatic Solid Tumors to Be Presented at ESMO Congress 2019

Sep 23, 2019 7:05am EDT

Preliminary Results From IMV’s Phase 2 Basket Trial Evaluating DPX-Survivac as a Combination Therapy in Patients with Advanced and Metastatic Solid Tumors to Be Presented at ESMO Congress 2019

Sep 04, 2019 7:05am EDT

IMV Announces Research Collaboration with The Wistar Institute to Develop New Targeted Immunotherapy Against the Common BRAF Cancer Mutation

Aug 22, 2019 7:05am EDT

IMV Inc. to Present at Upcoming Investor Conferences

Aug 08, 2019 5:05pm EDT

IMV Inc. Announces Second Quarter 2019 Financial Results and Provides Company Update

Jul 26, 2019 4:00pm EDT

IMV Inc. to Present at the Canaccord Genuity 39th Annual Growth Conference

RSS
  • Prev
  • 1
  • 2
  • 3
  • 4
  • 5
  • 6
  • 7
  • 8
  • 9
  • 10
  • ...35
  • Next
  • Email Alerts
  • Contacts
  • RSS News Feed
IMV Inc.
About Us The DPX Platform Clinical Pipeline News & Events Investors Careers Contact
Twitter LinkedIn Youtube
© 2021 IMV Inc. All Rights Reserved.
Privacy Policy Disclaimer Sitemap